Anti-CEA-CAR-T Cells is under clinical development by Shanghai First Song Therapeutics and currently in Phase I for Small Intestine Cancer. According to GlobalData, Phase I drugs for Small Intestine Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Anti-CEA-CAR-T Cells LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anti-CEA-CAR-T Cells overview
The therapeutic candidate is under development for the treatment of advanced and metastatic solid tumors including gastric cancer, colorectal cancer, esophageal cancer, small bowel cancer, pancreas adenocarcinoma and other digestive system tumors. It is administered through intravenous route and comprises of T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting carcinoembryonic antigen (CEA) expressing cells.
Shanghai First Song Therapeutics overview
Shanghai First Song Therapeutics is a innovative biotechnology company provide manufacturing, developing and commercializing cell immunotherapy products. The company is headquartered in China.
For a complete picture of Anti-CEA-CAR-T Cells’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
